Why CannTrust (TSX:TRST) Stock Declined Over 4% Yesterday

Why it’s still risky to invest in CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST).

A stock price graph showing declines

Image source: Getty Images.

It seems there is no respite for CannTrust (TSX:TRST)(NYSE:CTST) investors. CannTrust stock was down 4.1% yesterday after the company announced that products worth $2.9 million were returned by the Ontario Cannabis Store (OCS). The OCS, which is in charge of Canada’s wholesale to retail distribution, deemed the products to be “non-conforming.”

This is the latest drawback for CannTrust and its investors. Last month, CannTrust shares fell over 50% after it was revealed that the company was manufacturing cannabis in unlicensed facilities. Government authorities such as Health Canada and the Ontario Securities Commission were forced to step in and are leading parallel investigations.

CannTrust’s auditor KMPG also withdrew its company audit report for 2018 and the first quarter of 2019. KPMG claimed that the audits were inaccurate. Yesterday, The Schall Law Firm filed a class-action suit against CannTrust. The law firm accused CannTrust of false and misleading statements, due to which investors suffered substantial damages

CannTrust investors have lost a whopping 80% since March this year. So, has the stock bottomed out?

A lot depends on regulatory bodies

CannTrust stopped the sales of products across segments shortly after the manufacturing scandal went public. The total inventory on hold has been valued at $51 million. It was later revealed that Health Canada has found another facility that did not comply with regulations.

Investors will be waiting with bated breath for the outcome of these investigations. In case Health Canada levies a fine that is not too hefty, expect CannTrust’s stock to move significantly higher. The company can also then restart operations and focus on core strategies.

However, will the regulatory bodies suspend CannTrust’s licences or revoke manufacturing permits? Will CannTrust, a company currently valued at $400 million, cease to exist?

Cannabis companies are under the microscope

According to a Forbes article last week, the Federal Bureau of Investigation (FBI) is looking into corruption activities in the cannabis industry.

FBI Public Affairs Specialist Mollie Harpen stated, “States require licenses to grow and sell the drug — opening the possibility for public officials to become susceptible to bribes in exchange for those licences. The corruption is more prevalent in western states where the licensing is decentralized — meaning the level of corruption can span from the highest to the lowest level of public officials.”

Other leading cannabis companies such as Curaleaf Holdings and HEXO are also facing regulatory problems. Last month, Curaleaf received a warning from the Food and Drug Administration for misleading claims on products.

HEXO was accused of aggressively promoting products on social media platform Snapchat. While HEXO was accused by a short-seller, the Snapchat platform is popular among the underaged populace and might cause a problem for the company.

It seems like cannabis companies are coming under the regulatory radar, and for good reason. Investors expect the highest level of ethics by the management of publicly traded companies.

Any behaviour short of investor expectations will result in massive pullbacks, as has been the case with several cannabis stocks.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »